Inclusion Criteria:

• Provided signed written informed consent.
• Men and woman age > 18 years
• Histologically confirmed R0 OR R1 resected ductal adenocarcinoma of the pancreas
• Life expectancy >12 weeks
• Patients with performance status of ECOG ≤ 2
• Patients without metastasis

Exclusion Criteria:

• Women of child bearing potential (WOCP) who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and follow-up to 4 weeks after the study.
• Women who are pregnant or breastfeeding.
• Women with a positive pregnancy test on enrollment or prior to study drug administration.
• Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.
• Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of the cervix. (Patients with a previous malignancy but without evidence of disease for > 5 years will be allowed to enter the trial).
• Inadequate hematologic function defined by an absolute neutrophils count (ANC) < 1,500/mm³, a platelet count < 100,000/mm³ and a hemoglobin < 9 g/dL.
• Inadequate hepatic function defined by the upper limit of normal (ULN), AST and ALT levels > 5 times the ULN.
• Serum bilirubin > 1.5 times the ULN.
• Inadequate renal function defined by a serum creatinine > 1.5 times the ULN.
• Prior cetuximab or other therapy that targets the EGF pathway.
• Prior antibody therapy.
• Any known allergic reaction against cetuximab.
• Any concurrent chronic systemic immune therapy, radiation therapy, hormonal therapy (except for physiological replacement), or any other investigational agents.
• HIV infection.
• Having participated in another clinical trial in the preceding 30 days.